Thymosin therapy in the DiGeorge syndrome.
Reconstruction of the T-cell immune defect in patients with the DiGeorge syndrome has been accomplished in the past by fetal thymus transplantation. Because of the risk of fatal graft-versus-host reaction with fetal thymus transplantation in patients with abnormal T-cell immunity, we have examined the effects of a thymus tissue extract, thymosin fraction 5, on the in vitro and in vivo immune function in children with the DiGeorge syndrome. T-cell numbers were increased with thymosin F5 in vitro in three of five patients. T-cell number and function was improved in three of four patients treated with thymosin F5 in vivo. Spontaneous improvement in the immune function of these patients cannot be excluded. These results suggest, however, that further trials with thymosin F5 therapy may be indicated in patients with the DiGeorge syndrome.
D004062:DiGeorge Syndrome / Q000188:drug therapy*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D013947:Thymosin / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D013951:Thymus Hormones; D013947:Thymosin